Product Hopping Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution. We assisted counsel in evaluating potential damages in a case where a branded pharmaceutical company was accused of harming competition by introducing new versions of a drug with longer remaining patent protection and withdrawing older versions of the drug.

In cases of product hopping by pharmaceutical manufacturers, what is the practice accused of?